Medicine:TurkoVac
From HandWiki
Revision as of 15:34, 17 April 2022 by imported>S.Timg (add)
Short description: Vaccine candidate against COVID-19
| Vaccine description | |
|---|---|
| Target disease | SARS-CoV-2 |
| Type | Killed/Inactivated |
| Clinical data | |
| Other names | ERUCOV-VAC |
| Routes of administration | Intramuscular |
TURKOVAC[1] (pronunciation: ['tɜ:rkəvæk]) (temporarily named as ERUCOV-VAC[2]) is a COVID-19 vaccine candidate developed by Health Institutes of Turkey and Erciyes University.
Clinical trials
In November 2020, TURKOVAC started on phase I trials with 44 participants in Turkey.[3]
In February 2021, TURKOVAC started on phase II trials with 250 participants in Turkey.[4]
In June, TURKOVAC started on phase III trials with 40,800 participants in Turkey.[5]
References
- ↑ "Turkey names home-grown COVID-19 jab Turkovac". Anadolu Agency. 22 June 2021. https://www.aa.com.tr/en/health/turkey-names-home-grown-covid-19-jab-turkovac/2281883.
- ↑ "Domestic COVID-19 jab Turkovac begins Phase 3 trials in Turkey". Daily Sabah. 22 June 2021. https://www.dailysabah.com/turkey/domestic-covid-19-jab-turkovac-begins-phase-3-trials-in-turkey/news.
- ↑ Clinical trial number NCT04691947 for "Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC (ERUCOV-VAC)" at ClinicalTrials.gov
- ↑ Clinical trial number NCT04824391 for "Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19 " at ClinicalTrials.gov
- ↑ "Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) Versus the CoronaVac Vaccine". ClinicalTrials.gov. 28 June 2021. NCT04942405. Retrieved 29 June 2021.
 |
